oPatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.
Diabetes mellitus is a disease caused by deficiency or diminished effectiveness of endogenous insulin. It is characterised by hyperglycaemia, deranged metabolism and sequelae predominantly affecting the vasculature. The main types of diabetes mellitus are:
- Type 1 diabetes mellitus: results from the body's failure to produce sufficient insulin.
- Type 2 diabetes mellitus: results from resistance to the insulin, often initially with normal or increased levels of circulating insulin.
- Gestational diabetes: pregnant women who have never had diabetes before but who have high blood glucose levels during pregnancy are said to have gestational diabetes. Gestational diabetes affects about 4% of all pregnant women. It may precede development of type 2 (or rarely type 1) diabetes.
- Maturity-onset diabetes of the young (MODY) includes several forms of diabetes with monogenetic defects of beta-cell function (impaired insulin secretion), usually manifesting as mild hyperglycaemia at a young age, and usually inherited in an autosomal-dominant manner.
- Secondary diabetes: accounts for only 1-2% of patients with diabetes mellitus. Causes include:
- Pancreatic disease: cystic fibrosis, chronic pancreatitis, pancreatectomy, carcinoma of the pancreas.
- Endocrine: Cushing's syndrome, acromegaly, thyrotoxicosis, phaeochromocytoma, glucagonoma.
- Drug-induced: thiazide diuretics, corticosteroids, atypical antipsychotics, antiretroviral protease inhibitors.
- Congenital lipodystrophy.
- Acanthosis nigricans.
- Genetic: Wolfram's syndrome (which is also referred to as DIDMOAD: diabetes insipidus, diabetes mellitus, optic atrophy and deafness), Friedreich's ataxia, dystrophia myotonica, haemochromatosis, glycogen storage diseases.
Some patients with type 2 diabetes require insulin, so the old terms of insulin-dependent diabetes mellitus (IDDM) for type 1 diabetes and non-insulin-dependent diabetes mellitus (NIDDM) for type 2 diabetes are inappropriate. Type 2 diabetes is increasingly diagnosed in children and adolescents and so the old term maturity-onset diabetes for type 2 diabetes is also inappropriate.
Type 1 diabetes mellitus
The development of type 1 diabetes mellitus is based on a combination of a genetic predisposition and an autoimmune process that results in gradual destruction of the beta cells of the pancreas, leading to absolute insulin deficiency. There is usually a pre-diabetic phase where autoimmunity has already developed but with no clinically apparent insulin dependency. Insulin autoantibodies can be detected in genetically predisposed individuals as early as 6-12 months of age.
Possible triggers for the process may include viruses, dietary factors, environmental toxins, and emotional or physical stress. Early cessation of breast-feeding has also been linked to increased risk of developing type 1 diabetes, but the association is unproven and controversial.
- Approximately 15% of those with diabetes have type 1 diabetes - usually juvenile-onset, but it may occur at any age. It may be associated with other autoimmune diseases. It is characterised by insulin deficiency.
- There is 30-50% concordance in identical twins and a positive family history in 10% of people with type 1 diabetes. Screening for the diagnosis of diabetes in first-degree relatives of patients with type 1 is therefore reasonable, keeping in mind that the absolute risk is quite low.
- Associated with HLA DR3 and DR4 and islet cell antibodies around the time of diagnosis.
- Patients always need insulin treatment and are prone to ketoacidosis.
- The most at-risk population for type 1 diabetes is Caucasian of northern European ancestry. Incidence is high in Scandinavian people.
Type 2 diabetes mellitus
- Approximately 85% of those with diabetes; they are usually older at presentation (usually >30 years of age) but it is increasingly diagnosed in children and adolescents.
- Type 2 diabetes is associated with excess body weight and physical inactivity.
- All racial groups are affected but there is increased prevalence in people of South Asian, African, African-Caribbean, Polynesian, Middle-Eastern and American-Indian ancestry.
- It is caused by impaired insulin secretion and insulin resistance and has a gradual onset.
- Those with type 2 diabetes may eventually need insulin treatment.
- In 2011 there were 2.9 million people with diabetes. It is estimated that 5 million people will have diabetes in the UK by 2025.
- It is estimated that there are around 850,000 people in the UK who have diabetes but have not been diagnosed.
- The UK average prevalence of diabetes in the UK is 4.45% but there are variations between countries and regions.
- The proportion of people with diabetes increases with age.
- However, the incidence of diabetes is increasing in all age groups. Type 1 diabetes is increasing in children (especially those aged <5 years), and type 2 diabetes is increasing, particularly in black and minority ethnic groups.
Risk factors for type 2 diabetes
- Obesity, especially central (truncal) obesity.
- Lack of physical activity.
- Ethnicity: people of South Asian, African, African-Caribbean, Polynesian, Middle-Eastern and American-Indian descent are at greater risk of type 2 diabetes, compared with the white population.
- History of gestational diabetes.
- Impaired glucose tolerance.
- Impaired fasting glucose.
- Drug therapy - eg, combined use of a thiazide diuretic with a beta-blocker.
- Low-fibre, high-glycaemic index diet.
- Metabolic syndrome.
- Polycystic ovarian syndrome.
- Family history (2.4-fold increased risk for type 2 diabetes).
- Adults who had low birth weight for gestational age.
- Patients with all types of diabetes may present with polyuria, polydipsia, lethargy, boils, pruritus vulvae or with frequent, recurrent or prolonged infections.
- Patients with type 1 diabetes may also present with weight loss, dehydration, ketonuria and hyperventilation. Presentation of type 1 diabetes tends to be acute with a short duration of symptoms.
- Presentation in patients with type 2 diabetes tends to be subacute with a longer duration of symptoms.
- Patients with diabetes may present with acute or chronic complications, as outlined in the section 'Complications', below.
- Diabetes may be diagnosed on the basis of one abnormal plasma glucose (random ≥11.1 mmol/L or fasting ≥7 mmol/L) in the presence of diabetic symptoms such as thirst, increased urination, recurrent infections, weight loss, drowsiness and coma.
- In asymptomatic people with an abnormal random plasma glucose, two fasting venous plasma glucose samples in the abnormal range (≥7 mmol/L) are recommended for diagnosis.
- Two-hour venous plasma glucose concentration ≥11.1 mmol/L two hours after 75 g anhydrous glucose in an oral glucose tolerance test (OGTT).
- The World Health Organization (WHO) now recommends that glycated haemoglobin (HbA1c) can be used as a diagnostic test for diabetes. An HbA1c of 48 mmol/mol (6.5%) is recommended as the cut-off point for diagnosing diabetes. A value less than 48 mmol/mol does not exclude diabetes diagnosed using glucose tests. See also the separate article on Glycated Haemoglobin.
Assessment and monitoring
- Assessment: see the separate article on Assessment of the Patient with Established Diabetes.
- Monitoring: see the separate articles on Glycated Haemoglobin and Self-Monitoring in Diabetes Mellitus.
The management plan for a person with diabetes includes:
- Diabetes education: structured education and self-management (at diagnosis and regularly reviewed and reinforced) to promote awareness.
- Diet and lifestyle: healthy diet, weight loss if the person is overweight, smoking cessation, regular physical exercise.
- Maximising glucose control while minimising adverse effects of treatment, such as hypoglycaemia.
- Reduction of other risk factors for complications of diabetes, including the early detection and management of hypertension, drug treatment to modify lipid levels and consideration of antiplatelet therapy with aspirin.
- Monitoring and early intervention for complications of diabetes, including cardiovascular disease, feet problems, eye problems, kidney problems and neuropathy.
A global assessment of an individual's cardiovascular risk is essential.
See the separate articles:
- Management of Type 1 Diabetes
- Management of Type 2 Diabetes
- The Patient with Newly-diagnosed Diabetes
- Diabetes Diet and Exercise
- Diabetes Education and Self-management Programmes
- Antihyperglycaemic Agents used for Type 2 Diabetes
- Insulin Regimens
- Precautions with Patients with Diabetes Undergoing Surgery
- Diabetes and Intercurrent Illness
- Diabetes in Pregnancy
- Gestational Diabetes
Refer to the separate articles under 'Acute' and 'Chronic' headings in this section.
- See Diabetic Ketoacidosis and Hyperosmolar Hyperglycaemic State.
- See Emergency Management of Hypoglycaemia.
- Cardiovascular disease: see ischaemic heart disease (Stable Angina, Acute Coronary Syndrome), Cerebrovascular Events and Peripheral Arterial Disease.
- See Diabetic Nephropathy.
- See Diabetic Retinopathy and Diabetic Eye Problems.
- See Diabetic Neuropathy, Autonomic Neuropathy and Neuropathic Pain and its Management.
- See Diabetic Foot, Leg Ulcers and Painful Foot.
- Frequent, recurrent and persistent infections.
- Type 1 diabetes:
- Many people with type 1 diabetes have good health but there is an increased risk of blindness, end-stage renal disease, cardiovascular disease and, in some cases, early death.
- Controlling blood glucose, lipids, blood pressure and weight are important prognostic factors.
- Type 2 diabetes:
- 75% of people with type 2 diabetes will die of heart disease and 15% of stroke.
- The mortality rate from cardiovascular disease is up to five times higher in people with diabetes than in people without diabetes.
- For every 1% increase in HbA1c level, the risk of death from a diabetes-related cause increases by 21%.
There is now an emerging interest as to whether vaccination can be applied in autoimmune and inflammatory conditions. Vaccination may have a future role in the prevention of type 1 diabetes.
Type 2: see the separate article on Prevention of Type 2 Diabetes.
Further reading & references
- Guidelines on diabetes, pre-diabetes, and cardiovascular diseases, European society of cardiology developed in collaboration with the EASD (2013)
- Diabetes guidelines; NICE
- Diabetes UK
- Maturity-onset Diabetes of The Young, Online Mendelian Inheritance in Man (OMIM)
- Wolfram Syndrome 1, WFS1; Online Mendelian Inheritance in Man (OMIM)
- Dunger DB, Todd JA; Prevention of type 1 diabetes: what next? Lancet. 2008 Nov 15;372(9651):1710-1. Epub 2008 Sep 22.
- Knip M, Virtanen SM, Akerblom HK; Infant feeding and the risk of type 1 diabetes. Am J Clin Nutr. 2010 May;91(5):1506S-1513S. doi: 10.3945/ajcn.2010.28701C. Epub 2010 Mar 24.
- Diabetes in the UK 2012 - Key statistics on diabetes; Diabetes UK, April 2012
- Diabetes - type 2; NICE CKS, July 2010
- Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus; World Health Organization, 2011
- Diabetes - type 1; NICE CKS, Dec 2010
- Wherrett DK, Daneman D; Prevention of type 1 diabetes. Pediatr Clin North Am. 2011 Oct;58(5):1257-70, xi.
- Haller MJ, Atkinson MA, Schatz DA; Efforts to prevent and halt autoimmune beta cell destruction. Endocrinol Metab Clin North Am. 2010 Sep;39(3):527-39. doi: 10.1016/j.ecl.2010.05.006.
- Peakman M; Can we vaccinate against Type 1 diabetes? F1000 Biol Rep. 2012;4:19. doi: 10.3410/B4-19. Epub 2012 Oct 2.
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.
|Original Author: Dr Hayley Willacy||Current Version: Dr Colin Tidy||Peer Reviewer: Dr John Cox|
|Last Checked: 02/07/2013||Document ID: 2048 Version: 30||© EMIS|